查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1832132

解剖病理學檢測市場（按檢測類型、樣本類型、應用和最終用戶分類）—2025-2032 年全球預測

Anatomic Pathology Testing Market by Test Type, Sample Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年解剖病理學測試市場將成長至 740.1 億美元，複合年成長率為 6.40%。

主要市場統計數據
基準年2024年 450.3億美元
預計2025年 479.2億美元
預測年份：2032年 740.1億美元
複合年成長率（%） 6.40%

整合技術創新、不斷變化的臨床需求、實驗室工作流程和政策促進因素的解剖病理學檢測趨勢概述

解剖病理學檢測正處於臨床需求與快速技術創新的交匯點，推動著人們對診斷準確性、週轉時間以及與治療決策整合的全新期望。如今，在實驗室和診斷服務機構所處的環境中，分子表徵、免疫分析和影像主導分析必須與傳統的組織學工作流程共存，以支持精準醫療路徑。因此，臨床、研究和商業領域的相關人員正在重新調整投資、夥伴關係和營運流程，以應對日益複雜的臨床需求，同時控制成本並確保合規性。

此外，醫療保健服務模式的轉變（從門診腫瘤項目到集中式參考實驗室）正在改變檢體流程、檢測量和診斷決策場所。因此，實驗室負責人不僅在評估數位和分子工具集的診斷價值，還在評估其與電子健康記錄、實驗室資訊系統和多學科護理團隊的整合能力。鑑於這些動態，以下高階主管綜合報告確定了再形成實踐的關鍵促進因素、需要策略應對的結構性挑戰，以及決策者在優先考慮人員、技術和夥伴關係關係投資時應權衡的實際因素。

深入檢驗正在重塑診斷途徑、資料架構和實驗室人員的變革性技術、臨床和監管變化

解剖病理學領域正在經歷數次變革，這些變革正在改變診斷方式、實驗室運作方式以及數據在相關人員之間的流動方式。許多機構已將數位病理學從試點階段推進到實際應用階段，實現了全切片成像、遠端審查和演算法影像分析的應用。同時，人工智慧和機器學習在日常工作流程中的普及，為診斷演算法檢驗、臨床整合和法規核准帶來了新的考量。

同時，次世代定序、螢光原位雜合反應和標靶 PCR 等分子病理學技術正在重新定義診斷類別和治療分層。這種分子生物學擴展需要組織病理學和分子生物學實驗室之間加強合作，對生物資訊學、資料儲存和跨學科培訓的需求也日益增加。監管關注和報銷框架也在不斷發展。因此，實驗室必須應對不斷變化的驗證期望和價值證明要求。最後，實驗室面臨實驗室緊張、供應鏈不穩定以及對更快週轉時間日益成長的需求，這促使它們尋求自動化、簡化的工作流程和策略供應商合作夥伴關係，以維持品質和產量。總之，這些轉變正在重塑採購、勞動力發展和臨床服務設計的優先事項。

重點分析2025年美國關稅改革如何改變供應鏈、採購策略、試劑採購和跨境實驗室營運

美國關稅政策在2025年之前的演變，將對從事解剖病理學檢測的實驗室、製造商和經銷商產生複雜的營運和策略影響。短期內，進口設備、試劑和耗材關稅的提高，迫使採購團隊重新評估籌資策略，增加關鍵試劑的庫存緩衝，並加快供應商資格資格確認流程，以降低供應中斷的風險。因此，採購週期通常包含緊急條款、替代供應商清單和加速檢驗途徑，以確保臨床服務的連續性。

從中期來看，這些貿易行動凸顯了供應商多元化和區域採購的經濟和物流價值。一些臨床實驗室和製造合作夥伴正在尋求更緊密的製造合作，擴大製造外包，並實現倉儲本地化，以降低運費波動和關稅風險。同時，製造商正在重新審視產品設計和零件採購，以減少受關稅影響零件的風險，而服務機構也正在重新評估其維護和備件策略。當供應商更換來源時，也會產生監管和合約方面的影響。因此，機構必須確保替換零件符合原始性能和監管基準。

此外，關稅主導的成本壓力可能會加速圍繞自動化和檢測整合的討論，這將減少對進口耗材的逐項檢測依賴。為了因應這些壓力，相關人員越來越重視情境規劃、包含對沖條款的多年期供應商合約以及與供應夥伴的協作預測。總而言之，2025 年的關稅趨勢正在推動策略轉變，轉向供應彈性、採購敏捷性以及加強產業與實驗室之間的協作，以保障診斷的連續性。

按測試類型、樣本類型、應用程式和最終用戶進行細分，以揭示採用動態、技術協作和優先級

按測試類型分析表明，實驗室正在建立混合診斷工作流程，在傳統組織學技術與新興的數位和分子模式之間取得平衡。數位病理學正在吸引對影像分析軟體和玻片掃描儀的投資，這些軟體和掃描儀可以進行遠端審查和高級形態學分析，而蘇木精-伊紅染色仍然是基本的組織評估方法。免疫組織化學繼續擴大其在診斷和預測測試中的作用，實驗室根據檢測特異性和供應可靠性使用單株和多株抗體策略。分子病理學已成為組織學的核心補充。診斷組合結合了螢光原位雜合反應、次世代定序和聚合酵素鏈鎖反應等方法，以捕捉基因組變異和可操作的生物標記。特殊染色技術，如過碘酸-希夫染色、銀染色和三色染色，對於特殊診斷情況和區分疾病形式非常重要。

在考慮樣本類型時，細胞學樣本、冷凍切片和組織切片檢查之間的差異決定了不同的分析前處理、預期週轉時間和設備需求。這些針對檢體的具體要求決定了實驗室所採用的工作流程和驗證策略。在應用方面，檢測程序針對遺傳疾病評估、感染疾病檢測和腫瘤學診斷進行調整。遺傳評估進一步分為染色體異常和單基因異常的工作流程，傳染病檢查區分細菌和病毒病原體的檢測策略，腫瘤學通訊協定優先考慮腫瘤特異性檢測組，例如用於乳癌、肺癌和前列腺癌的檢測組。最後，最終用戶（診斷實驗室、醫院和研究機構）具有不同的採購週期、監管要求和人員配備模式，所有這些都會影響技術在醫療保健途徑中的部署和擴展方式。

對美洲、歐洲、中東和非洲以及亞太地區的基礎設施、報銷、人才和創新採用的區域洞察

區域動態對解剖病理學檢測技術的採用、部署和運作有重大影響。在美洲，臨床和研究實驗室受益於強勁的資本市場和成熟的報銷途徑，從而促進了數位病理學平台和複雜分子檢測的早期應用。隨著從都市區醫療中心向區域參考檢測中心的轉變，醫療服務提供者通常強調與癌症治療途徑的整合，並與專業檢測中心合作。

由於法律規範、報銷結構和基礎設施準備程度的差異，歐洲、中東和非洲的採用曲線各不相同。在歐洲部分地區，標準化的醫療保健系統和集中採購使得數位化工作流程能夠廣泛部署；而在其他地區，由於資金和勞動力的可用性參差不齊，需要製定更有針對性的分階段採用策略。同時，在中東和非洲部分地區，能力建設舉措和官民合作關係關係正開始彌補分子檢測和數位基礎設施的差距。

在亞太地區，高患者數量、快速的基礎設施投資以及本地製造能力的結合，正在加速高通量分子平台和自動化組織學解決方案的採用。國家策略優先考慮精準醫療和診斷現代化，推動了次世代定序、玻片掃描和遠距病理學服務的快速整合。綜上所述，這些區域模式表明，需要製定靈活的部署模式和針對特定區域的商業化方法，以滿足臨床需求和基礎設施現狀。

詳細了解儀器、試劑和軟體參與者的競爭策略、創新管道、合作模式和投資重點

該領域的企業行為體現了產品專業化、垂直整合和夥伴關係主導的擴張相結合。儀器製造商持續投資於自動化和互通性，設計可與影像分析軟體和實驗室資訊系統整合的玻片掃描器和實驗室平台。試劑和抗體製造商專注於產品組合的廣度和供應的穩定性，在專有配方和廣泛的分銷策略之間取得平衡，以降低臨床實驗室的單一來源風險。軟體供應商透過檢驗的演算法、可擴展的雲端架構和以用戶為中心的介面來脫穎而出，這些介面支援常規診斷工作流程以及高級研究應用。

儀器製造商、試劑供應商和軟體開發商之間的夥伴關係促成了捆綁解決方案，從而縮短了最終用戶的引進週期並簡化了檢驗工作。同時，一些公司正在進行有針對性的併購，以加速獲取互補能力，例如生物資訊學、雲端基礎設施和細分檢測專業知識。服務支援模式的重要性日益凸顯，實驗室現在期望獲得全面的培訓、遠端故障排除和效能保證。最後，公司越來越關注監管途徑和證據生成，優先進行臨床驗證研究和上市後檢驗，以確認診斷聲明並支持付款方的主張。

建議實驗室領導、技術開發人員和政策制定者採取以下行動，以加速臨床應用、改善營運並提高供應彈性

臨床實驗室負責人應優先考慮分階段的數位化應用策略，該策略從概念驗證部署開始，逐步推進到在清晰的檢驗通訊協定下實現大規模生產。從遠端二次抄表或高容量腫瘤板等目標用例入手，有助於組織展示臨床效用，完善與資訊系統的整合，並在進行更廣泛的部署之前建立機構信任。同時，採購團隊應實施供應商多元化和資格確認框架，以減少對單一來源試劑和組件的依賴。

技術開發者必須投資於可互通的設計和開放標準，以簡化與實驗室資訊系統和電子健康記錄的整合，並降低臨床應用的門檻。監管參與和透明的績效記錄至關重要。開發者應進行嚴格的臨床檢驗，並發布支持實際應用的同儕審查證據。政策制定者和支付方可以透過支援對經臨床驗證、能夠顯著提高診斷準確性和患者管理水平的數位和分子檢測進行試點報銷，來加速價值實現。

病理學家、組織學技術員和分子生物學家需要接受新平台的培訓，同時各機構應組成跨職能團隊，匯集實驗室科學家、資料工程師和臨床相關人員，將洞察實用化為診療路徑。這些綜合行動將增強韌性，最佳化資源配置，並實現永續應用。

簡明的調查方法，說明多源資料收集、專家訪談、證據三角測量和分析保障措施，以確保嚴謹性

本研究採用混合方法，強調三角測量和透明度。透過對同行評審文獻、監管指南文件、已發表的臨床研究和公開文件進行二次分析，建立了背景基礎。資訊來源，還進行了初步定性研究，包括對實驗室主任、病理學主任、採購主管、技術開發人員和臨床最終用戶進行結構化訪談，以揭示營運現狀、驗證實踐和策略重點。

分析保障措施包括將聲明與監管部門的核准和已發表的臨床證據進行交叉驗證，以及基於場景的敏感性檢查，以檢查操作變量，例如周轉要求和試劑交付前置作業時間。資料完整性流程包括檢驗訪談記錄、主題編碼以識別趨同見解，以及系統地記錄假設和納入標準。主要訪談涵蓋不同的地理和地點概況，但區域差異可能因當地政策和報銷狀況而異。訪談參與者提供了知情同意，專有資訊根據保密規則處理。這些方法相結合，可實現嚴格、審核的綜合，旨在為實際決策提供資訊。

總結綜合技術進步、臨床需求、監管壓力和營運回應，為相關人員提供指導

總而言之，解剖病理學檢測生態系統正處於一個關鍵的十字路口，技術能力正滿足不斷變化的臨床期望。數位病理學、先進的免疫組織化學方法和不斷擴展的分子診斷技術共同促成了更準確、更可操作的診斷，但也需要製定一個協調一致的整合、檢驗和人才培養策略。監管變化和商業動態進一步創造了一種環境，在這種環境中，韌性、適應性和證據生成是至關重要的競爭和營運差異化因素。

因此，相關人員應尋求切實可行的分階段採用路徑，加強與供應商的關係，並投資於可互通的系統，以減少整個診斷工作流程中的摩擦。透過將臨床目標與強大的驗證和數據管治實踐相結合，實驗室可以將技術能力與診斷品質和護理協調方面的可衡量改進聯繫起來。最終，能夠平衡臨床嚴謹性、營運效率和策略夥伴關係的組織將最有能力提供永續的診斷價值，從而促進患者照護。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 推出用於遠距離診斷協作的人工智慧驅動的數位病理平台
  • 開發用於全面腫瘤分析的多重免疫組織化學檢測方法
  • 液態生物檢體與組織病理學工作流程的整合，用於早期癌症檢測
  • 監管核准批准推動精準醫療人工智慧病理學工具的商業化
  • 標準化數位幻燈片掃描通訊協定以提高機構之間的數據相容性
  • 引入雲端基礎的病理資訊系統以簡化檢測操作
  • 個人化腫瘤治療計劃中人工智慧預測生物標記的新興趨勢

第6章 2025年美國關稅的累積影響

第7章：人工智慧2025的累積影響

8. 解剖病理學檢測市場（依檢測類型）

  • 數位病理學
    • 影像分析軟體
    • 幻燈片掃描儀
  • 蘇木精和伊紅染色
  • 免疫組織化學
    • 單株抗體
    • 多株抗體
  • 分子病理學
    • 螢光原位雜合反應
    • 次世代定序
    • 聚合酵素鏈鎖反應
  • 特殊染色技術
    • 過碘酸-希夫染色
    • 銀色染色
    • 三色染色

9. 解剖病理學檢測市場（依樣本類型）

  • 細胞學樣本
  • 冰凍切片
  • 組織切片檢查

第 10 章解剖病理學測試市場（按應用）

  • 遺傳疾病評估
    • 染色體異常
    • 單基因異常
  • 感染疾病檢測
    • 細菌感染
    • 病毒感染
  • 腫瘤診斷
    • 乳癌
    • 肺癌
    • 攝護腺癌

第 11 章解剖病理學測試市場（按最終用戶）

  • 診斷實驗室
  • 醫院
  • 研究所

第12章解剖病理學檢測市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章解剖病理學測試市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 解剖病理學檢測市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Laboratory Corporation of America Holdings
    • Quest Diagnostics Incorporated
    • Sonic Healthcare Limited
    • Eurofins Scientific SE
    • SYNLAB Holding GmbH
    • Unilabs AG
    • Bio-Reference Laboratories, Inc.
    • ARUP Laboratories, Inc.
    • Dr. Lal PathLabs Limited
    • Metropolis Healthcare Limited
Product Code: MRR-436901066173

The Anatomic Pathology Testing Market is projected to grow by USD 74.01 billion at a CAGR of 6.40% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 45.03 billion
Estimated Year [2025] USD 47.92 billion
Forecast Year [2032] USD 74.01 billion
CAGR (%) 6.40%

An introductory overview of anatomic pathology testing trends integrating technological innovation, clinical demand shifts, laboratory workflows, policy drivers

Anatomic pathology testing stands at the intersection of clinical necessity and rapid technological change, driving new expectations for diagnostic accuracy, turnaround time, and integration with therapeutic decision-making. Laboratories and diagnostic services now operate in an environment where molecular characterization, immunoprofiling and image-driven analytics must co-exist with traditional histology workflows to support precision medicine pathways. Consequently, stakeholders across clinical, research and commercial settings are recalibrating investments, partnerships and operational processes to meet rising clinical complexity while controlling costs and ensuring regulatory compliance.

Furthermore, shifts in healthcare delivery-from outpatient oncology programs to centralized reference labs-have altered specimen flows, testing volumes and the locus of diagnostic decision-making. As a result, laboratory leaders are evaluating digital and molecular toolsets not only for their diagnostic value but for their ability to integrate into electronic health records, laboratory information systems and multidisciplinary care teams. In light of these dynamics, the executive synthesis that follows highlights the major drivers reshaping practice, the structural challenges that require strategic response, and the practical considerations that decision-makers should weigh when prioritizing investments in people, technology and partnerships.

A detailed examination of transformative technological, clinical and regulatory shifts reshaping diagnostic pathways, data architecture and laboratory workforce

The landscape of anatomic pathology testing is undergoing several transformative shifts that are changing how diagnoses are made, how laboratories organize work, and how data flows between stakeholders. Digital pathology adoption has progressed from pilot installations to production deployments in many institutions, enabling whole slide imaging, remote review and the application of algorithmic image analysis. At the same time, the diffusion of artificial intelligence and machine learning into routine workflows has introduced new considerations around validation, clinical integration and regulatory clearance of diagnostic algorithms.

Concurrently, molecular pathology techniques such as next-generation sequencing, fluorescence in situ hybridization and targeted PCR are redefining diagnostic categories and therapeutic stratification. This molecular expansion necessitates increased collaboration between histopathology and molecular laboratories, and it elevates demands on bioinformatics, data storage and cross-discipline training. Regulatory attention and reimbursement frameworks are also evolving; as a result, laboratories must navigate changing validation expectations and value demonstration requirements. Lastly, workforce pressures, supply chain volatility and increasing demand for faster turnaround times are prompting laboratories to seek automation, streamlined workflows and strategic vendor partnerships to sustain quality and throughput. Taken together, these shifts are reshaping priorities across procurement, talent development and clinical service design.

A focused analysis of how United States tariff changes in 2025 are altering supply chains, procurement tactics, reagent sourcing and cross-border lab operations

United States tariff policy developments in 2025 have produced a complex set of operational and strategic effects for laboratories, manufacturers and distributors involved in anatomic pathology testing. In the short term, tariff-induced increases on imported instruments, reagents and consumables have compelled procurement teams to reassess sourcing strategies, increase inventory buffers for critical reagents and accelerate supplier qualification processes to reduce exposure to supply disruption. Consequently, procurement cycles now often include contingency clauses, alternative supplier lists and accelerated validation pathways to ensure continuity of clinical services.

Over the medium term, these trade measures have highlighted the economic and logistical value of supplier diversification and regionalized sourcing. Some clinical laboratories and manufacturing partners have pursued nearer-shore manufacturing partnerships, contract manufacturing expansions and localized warehousing to mitigate freight volatility and duty risk. At the same time, manufacturers are revisiting product design and bill-of-materials sourcing to reduce exposure to tariffed components, while service organizations are re-evaluating maintenance and spare parts strategies. Regulatory and contractual implications also surface when suppliers change sourcing origins; therefore, institutions must ensure that any substituted components meet the original performance and regulatory benchmarks.

Moreover, tariff-driven cost pressures can accelerate conversations around automation and assay consolidation that reduce per-test dependency on imported consumables. To manage these pressures, stakeholders increasingly emphasize scenario planning, multi-year supplier agreements with hedging provisions, and collaborative forecasting with supply partners. In sum, tariff dynamics in 2025 are prompting a strategic reorientation toward supply resilience, procurement agility and stronger industry-lab collaboration to safeguard diagnostic continuity.

Segmentation-focused insights across test types, sample categories, applications and end users revealing adoption dynamics, technology linkages and priorities

Analysis by test type reveals that laboratories are balancing legacy histology techniques with emergent digital and molecular modalities to create hybrid diagnostic workflows. Digital Pathology attracts investment in both image analysis software and slide scanners to enable remote review and advanced morphometric analysis, while Hematoxylin and Eosin staining remains the foundational tissue assessment method. Immunohistochemistry continues to expand its role for diagnostic and predictive testing, with laboratories weighing monoclonal versus polyclonal antibody strategies according to assay specificity and supply reliability. Molecular Pathology has become a core complement to histology; diagnostic portfolios blend fluorescence in situ hybridization, next-generation sequencing and polymerase chain reaction approaches to capture genomic alterations and actionable biomarkers. Special Staining techniques such as periodic acid-Schiff stain, silver stain and trichrome stain retain importance for niche diagnostic contexts and for distinguishing disease morphologies.

When sample type is considered, distinctions among cytology samples, frozen sections and tissue biopsy specimens drive differences in pre-analytic handling, turnaround expectations and instrumentation needs. These sample-specific demands in turn shape the workflows and validation strategies laboratories adopt. In terms of application, testing programs align with genetic disorder evaluation, infectious disease detection and oncology diagnostics. Genetic assessments further bifurcate into chromosomal versus single-gene disorder workflows, infectious disease testing delineates bacterial from viral pathogen detection strategies, and oncology protocols increasingly prioritize tumor-specific panels such as those used in breast, lung and prostate cancer contexts. Finally, end users including diagnostic laboratories, hospitals and research institutes have distinct procurement cycles, regulatory requirements and staffing models, all of which influence how technologies are deployed and scaled across care pathways.

Regional insight into infrastructure, reimbursement, talent and innovation adoption distinguishing the Americas, Europe, Middle East & Africa and Asia-Pacific

Regional dynamics exert a strong influence on the adoption, deployment and operationalization of anatomic pathology testing technologies. In the Americas, clinical and research laboratories benefit from robust capital markets and established reimbursement pathways, which facilitate early adoption of digital pathology platforms and complex molecular assays. Transitioning from urban medical centers to regional reference laboratories, providers often emphasize integration with oncology care pathways and partnerships with specialty testing centers.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks, reimbursement structures and infrastructure readiness leads to differentiated adoption curves. In parts of Europe, standardized healthcare systems and centralized procurement can support broad rollouts of validated digital workflows, whereas in other regions, variable funding and workforce availability necessitate more focused, incremental implementation strategies. Meanwhile, capacity-building initiatives and public-private partnerships in certain Middle East and African locales are beginning to address gaps in molecular testing and digital infrastructure.

Across Asia-Pacific, a combination of large patient volumes, rapid infrastructure investment and local manufacturing capabilities is accelerating uptake of both high-throughput molecular platforms and automated histology solutions. National strategies that prioritize precision medicine and diagnostic modernization are enabling faster integration of next-generation sequencing, slide scanning and telepathology services. Taken together, these regional patterns underline the need for adaptable deployment models and region-specific commercialization approaches to meet clinical demand and infrastructure realities.

An in-depth view of competitive strategies, innovation pipelines, partnership models and investment priorities among instrumentation, reagent and software players

Company behavior in this sector reflects a mix of product specialization, vertical integration and partnership-driven expansion. Instrumentation manufacturers continue to invest in automation and interoperability, designing slide scanners and laboratory platforms that integrate with image analysis software and laboratory information systems. Reagent and antibody suppliers focus on portfolio breadth and supply stability, balancing proprietary formulations with wider distribution strategies to reduce single-source risk for clinical laboratories. Software vendors are differentiating through validated algorithms, scalable cloud architectures and user-centered interfaces that support routine diagnostic workflows as well as advanced research applications.

Strategic collaboration remains a hallmark of competitive positioning: partnerships among instrument makers, reagent suppliers and software developers enable bundled solutions that shorten adoption cycles and simplify validation efforts for end users. Concurrently, some organizations pursue targeted mergers and acquisitions to accelerate access to complementary capabilities such as bioinformatics, cloud infrastructure or niche assay expertise. Service and support models have grown in importance as laboratories expect robust training, remote troubleshooting and performance guarantees. Finally, firms are increasingly attentive to regulatory pathways and evidence generation, prioritizing clinical validation studies and post-market surveillance to substantiate diagnostic claims and to support payer discussions.

Actionable recommendations for laboratory leaders, technology developers and policymakers to speed clinical adoption, improve operations and boost supply resilience

Laboratory leaders should prioritize a phased digital adoption strategy that begins with proof-of-concept deployments and progresses to scaled production under clear validation protocols. By starting with targeted use cases-such as remote secondary reads or high-volume tumor boards-organizations can demonstrate clinical utility, refine integration with information systems and build institutional confidence before committing to broader rollouts. In parallel, procurement teams should implement supplier diversification and qualification frameworks that reduce reliance on single-source reagents and parts; this will preserve operational continuity in the face of geopolitical or tariff-driven disruption.

Technology developers must invest in interoperable designs and open standards to ease integration with laboratory information systems and electronic health records, thereby lowering the barrier to clinical adoption. Regulatory engagement and transparent performance documentation are essential; developers should pursue rigorous clinical validation and publish peer-reviewed evidence that supports real-world use. Policy makers and payers can accelerate value realization by supporting pilot reimbursement schemes for clinically validated digital and molecular assays that demonstrably improve diagnostic accuracy or patient management.

Finally, workforce planning should combine targeted upskilling with role redesign: pathologists, histotechnologists and molecular specialists require training on new platforms, while organizations should create cross-functional teams that align laboratory scientists, data engineers and clinical stakeholders to operationalize insights into care pathways. These integrated actions will strengthen resilience, optimize resource allocation and enable sustainable adoption.

A concise methodology describing multi-source data collection, expert interviews, evidence triangulation and analytical safeguards applied to ensure rigor

This research applies a mixed-methods approach that emphasizes triangulation and transparency. Secondary analysis of peer-reviewed literature, regulatory guidance documents, published clinical studies and public filings established the contextual foundation. These sources were then augmented by primary qualitative research, including structured interviews with laboratory directors, heads of pathology, procurement executives, technology developers and clinical end users to surface operational realities, validation practices and strategic priorities.

Analytical safeguards included cross-validation of claims against regulatory approvals and published clinical evidence, as well as scenario-based sensitivity checks for operational variables such as turnaround requirements and reagent lead times. Data integrity processes encompassed interview transcription verification, thematic coding to identify convergent insights, and methodical documentation of assumptions and inclusion criteria. Limitations are acknowledged: while primary interviews spanned diverse geographies and institutional profiles, some regional nuance may vary by local policy and reimbursement contexts. Ethical considerations guided the work throughout; interview participants provided informed consent and proprietary information was handled under confidentiality protocols. Together, these methods support a rigorous and auditable synthesis intended to inform practical decision-making.

A concluding synthesis linking technological advances, clinical imperatives, regulatory pressures and operational responses to provide guidance for stakeholders

In conclusion, the anatomic pathology testing ecosystem is at a pivotal juncture where technological capability meets evolving clinical expectations. Digital pathology, advanced immunohistochemistry approaches and expanding molecular diagnostics collectively enable more precise, actionable diagnoses, but they also demand cohesive strategies for integration, validation and workforce development. Regulatory shifts and trade dynamics further contribute to an environment where resilience, adaptability and evidence generation are decisive competitive and operational differentiators.

Therefore, stakeholders should pursue pragmatic, staged adoption pathways, strengthen supplier relationships and invest in interoperable systems that reduce friction across diagnostic workflows. By aligning clinical objectives with robust validation and data governance practices, laboratories can translate technological potential into measurable improvements in diagnostic quality and care coordination. Ultimately, the organizations that balance clinical rigor, operational efficiency and strategic partnerships will be best positioned to deliver sustainable diagnostic value in service of patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of AI-driven digital pathology platforms for remote diagnostic collaboration
  • 5.2. Development of multiplex immunohistochemistry assays for comprehensive tumor profiling
  • 5.3. Emergence of liquid biopsy integration with histopathology workflows for early cancer detection
  • 5.4. Regulatory approvals driving the commercialization of AI pathology tools for precision medicine
  • 5.5. Standardization of digital slide scanning protocols to improve cross-institutional data compatibility
  • 5.6. Implementation of cloud-based pathology information systems to streamline lab operations
  • 5.7. Emerging trend of AI-enabled predictive biomarkers for personalized oncology treatment planning

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anatomic Pathology Testing Market, by Test Type

  • 8.1. Digital Pathology
    • 8.1.1. Image Analysis Software
    • 8.1.2. Slide Scanners
  • 8.2. Hematoxylin And Eosin Staining
  • 8.3. Immunohistochemistry
    • 8.3.1. Monoclonal Antibody
    • 8.3.2. Polyclonal Antibody
  • 8.4. Molecular Pathology
    • 8.4.1. Fluorescence In Situ Hybridization
    • 8.4.2. Next Generation Sequencing
    • 8.4.3. Polymerase Chain Reaction
  • 8.5. Special Staining
    • 8.5.1. Periodic Acid-Schiff Stain
    • 8.5.2. Silver Stain
    • 8.5.3. Trichrome Stain

9. Anatomic Pathology Testing Market, by Sample Type

  • 9.1. Cytology Samples
  • 9.2. Frozen Sections
  • 9.3. Tissue Biopsy

10. Anatomic Pathology Testing Market, by Application

  • 10.1. Genetic Disorders
    • 10.1.1. Chromosomal Disorders
    • 10.1.2. Single Gene Disorders
  • 10.2. Infectious Diseases
    • 10.2.1. Bacterial Infections
    • 10.2.2. Viral Infections
  • 10.3. Oncology
    • 10.3.1. Breast Cancer
    • 10.3.2. Lung Cancer
    • 10.3.3. Prostate Cancer

11. Anatomic Pathology Testing Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Anatomic Pathology Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anatomic Pathology Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anatomic Pathology Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Laboratory Corporation of America Holdings
    • 15.3.2. Quest Diagnostics Incorporated
    • 15.3.3. Sonic Healthcare Limited
    • 15.3.4. Eurofins Scientific SE
    • 15.3.5. SYNLAB Holding GmbH
    • 15.3.6. Unilabs AG
    • 15.3.7. Bio-Reference Laboratories, Inc.
    • 15.3.8. ARUP Laboratories, Inc.
    • 15.3.9. Dr. Lal PathLabs Limited
    • 15.3.10. Metropolis Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANATOMIC PATHOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANATOMIC PATHOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANATOMIC PATHOLOGY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA AN